These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38316077)

  • 21. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
    Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
    Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer's Disease.
    Sharma A; Angnes L; Sattarahmady N; Negahdary M; Heli H
    Biosensors (Basel); 2023 Jul; 13(7):. PubMed ID: 37504140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
    Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
    J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
    Vanderstichele H; De Vreese K; Blennow K; Andreasen N; Sindic C; Ivanoiu A; Hampel H; Bürger K; Parnetti L; Lanari A; Padovani A; DiLuca M; Bläser M; Olsson AO; Pottel H; Hulstaert F; Vanmechelen E
    Clin Chem Lab Med; 2006; 44(12):1472-80. PubMed ID: 17163825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
    Wilson EN; Young CB; Ramos Benitez J; Swarovski MS; Feinstein I; Vandijck M; Le Guen Y; Kasireddy NM; Shahid M; Corso NK; Wang Q; Kennedy G; Trelle AN; Lind B; Channappa D; Belnap M; Ramirez V; Skylar-Scott I; Younes K; Yutsis MV; Le Bastard N; Quinn JF; van Dyck CH; Nairn A; Fredericks CA; Tian L; Kerchner GA; Montine TJ; Sha SJ; Davidzon G; Henderson VW; Longo FM; Greicius MD; Wagner AD; Wyss-Coray T; Poston KL; Mormino EC; Andreasson KI
    Alzheimers Res Ther; 2022 Nov; 14(1):172. PubMed ID: 36371232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Immunosensor for the Determination of Cathepsin S in Blood Plasma by Array SPRi-A Comparison of Analytical Properties of Silver-Gold and Pure Gold Chips.
    Falkowski P; Mrozek P; Lukaszewski Z; Oldak L; Gorodkiewicz E
    Biosensors (Basel); 2021 Aug; 11(9):. PubMed ID: 34562888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders.
    Tzartos JS; Boufidou F; Stergiou C; Kuhle J; Willemse E; Palaiodimou L; Tsantzali I; Sideri E; Bonakis A; Giannopoulos S; Voumvourakis KI; Tsivgoulis G; Tzartos SJ; Kapaki E; Paraskevas GP
    Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36008993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers.
    Ashton NJ; Leuzy A; Karikari TK; Mattsson-Carlgren N; Dodich A; Boccardi M; Corre J; Drzezga A; Nordberg A; Ossenkoppele R; Zetterberg H; Blennow K; Frisoni GB; Garibotto V; Hansson O
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2140-2156. PubMed ID: 33677733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A New Approach to the Quantification of Fibroblast Growth Factor 23-An Array Surface Plasmon Resonance Imaging Biosensor.
    Tokarzewicz A; Ołdak Ł; Młynarczyk G; Klekotka U; Gorodkiewicz E
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
    Nägga K; Gottfries J; Blennow K; Marcusson J
    Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
    Kac PR; Gonzalez-Ortiz F; Simrén J; Dewit N; Vanmechelen E; Zetterberg H; Blennow K; Ashton NJ; Karikari TK
    Alzheimers Res Ther; 2022 May; 14(1):65. PubMed ID: 35545792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
    Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
    ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.